2. Academic Validation
  3. Entacapone and tolcapone, two catechol O-methyltransferase inhibitors, block fibril formation of alpha-synuclein and beta-amyloid and protect against amyloid-induced toxicity

Entacapone and tolcapone, two catechol O-methyltransferase inhibitors, block fibril formation of alpha-synuclein and beta-amyloid and protect against amyloid-induced toxicity

  • J Biol Chem. 2010 May 14;285(20):14941-14954. doi: 10.1074/jbc.M109.080390.
Saviana Di Giovanni 1,  Simona Eleuteri 2,  Katerina E Paleologou 1,  Guowei Yin 3,  Markus Zweckstetter 4,  Pierre-Alain Carrupt 5,  Hilal A Lashuel 6
Affiliations

Affiliations

  • 1 Laboratory of Molecular Neurobiology and Neuroproteomics, Swiss Federal Institute of Technology Lausanne, SV-BMI-LMNN-AI2351, CH-1015 Lausanne, Switzerland.
  • 2 Laboratory of Molecular Neurobiology and Neuroproteomics, Swiss Federal Institute of Technology Lausanne, SV-BMI-LMNN-AI2351, CH-1015 Lausanne, Switzerland; Dipartimento di Biologia Evoluzionistica Sperimentale, Università di Bologna Via Selmi, 3, 40126 Bologna, Italy.
  • 3 Max-Planck Institute for Biophysical Chemistry, NMR-based Structural Biology, Am Fassberg 11, 37077 Goettingen, Germany.
  • 4 Max-Planck Institute for Biophysical Chemistry, NMR-based Structural Biology, Am Fassberg 11, 37077 Goettingen, Germany; Deutsche Forschungsgemeinschaft Research Center for the Molecular Physiology of the Brain, Göttingen, Germany.
  • 5 School of Pharmaceutical Sciences, University of Geneva and University of Lausanne, Quai Ernest-Ansermet 30, CH-1211, Genève 4, Switzerland.
  • 6 Laboratory of Molecular Neurobiology and Neuroproteomics, Swiss Federal Institute of Technology Lausanne, SV-BMI-LMNN-AI2351, CH-1015 Lausanne, Switzerland. Electronic address: hilal.lashuel@epfl.ch.
PMID: 20150427 DOI: 10.1074/jbc.M109.080390
Abstract

Parkinson disease (PD) is the second most common neurodegenerative disorder after Alzheimer disease (AD). There is considerable consensus that the increased production and/or aggregation of alpha-synuclein (alpha-syn) plays a central role in the pathogenesis of PD and related synucleinopathies. Current therapeutic strategies for treating PD offer mainly transient symptomatic relief and aim at the restitution of dopamine levels to counterbalance the loss of dopaminergic neurons. Therefore, the identification and development of drug-like molecules that block alpha-synuclein aggregation and prevent the loss of dopaminergic neurons are desperately needed to treat or slow the progression of PD. Here, we show that entacapone and tolcapone are potent inhibitors of alpha-syn and beta-amyloid (Abeta) oligomerization and fibrillogenesis, and they also protect against extracellular toxicity induced by the aggregation of both proteins. Comparison of the anti-aggregation properties of entacapone and tolcapone with the effect of five other catechol-containing compounds, dopamine, pyrogallol, gallic acid, caffeic acid, and quercetin on the oligomerization and fibrillization of alpha-syn and Abeta, demonstrate that the catechol moiety is essential for the anti-amyloidogenic activity. Our findings present the first characterization of the anti-amyloidogenic properties of tolcapone and entacapone against both alpha-synuclein and Abeta42 and highlight the potential of this class of nitro-catechol compounds as anti-amyloidogenic agents. Their inhibitory properties, mode of action, and structural properties suggest that they constitute promising lead compounds for further optimization.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z